Sana Biotechnology Inc Stock News

Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025.

SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's curr...

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's Presid...

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update.

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.